12-hydroxy-eicosatetraenoic acid (12-HETE): A biomarker of Churg-Strauss syndrome

Clinical and Experimental Allergy

Volumn 42, Issue 4, 2012, Pages 513-522

  Szczeklik, W ^a   Sanak, M ^a   Mastalerz, L ^a   M Sokolowska B ^a   Gielicz, A ^a   Soja, J ^a   Kumik, J ^a   Musial J ^a   Szczeklik, A ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

12 HETE; Churg Strauss syndrome; Eicosanoids; Exhaled breath condensate; Vasculitis

Indexed keywords

12 HYDROXYICOSATETRAENOIC ACID; 12 TETRANOR HYDROXYICOSATETRAENOIC ACID; BIOLOGICAL MARKER; UNCLASSIFIED DRUG;

ADULT; ARTICLE; ASTHMA; BREATH ANALYSIS; CHURG STRAUSS SYNDROME; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MARKER; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HYPEREOSINOPHILIC SYNDROME; LUNG LAVAGE; MALE; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY;

12-HYDROXY-5,8,10,14-EICOSATETRAENOIC ACID; ADULT; BIOLOGICAL MARKERS; BREATH TESTS; BRONCHOALVEOLAR LAVAGE FLUID; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHURG-STRAUSS SYNDROME; EXHALATION; FEMALE; HUMANS; MALE; MIDDLE AGED; TANDEM MASS SPECTROMETRY;

EID: 84858313118     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/j.1365-2222.2011.03943.x     Document Type: Article

References (45)

1. Szczeklik W, Jakiela B, Adamek D, Musial J. Cutting edge issues in the Churg-Strauss syndrome. Clin Rev Allergy Immunol 2011; Epub ahead of print.
2. Guillevin L, Lhote F, Gayraud M et al. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. Medicine (Baltimore) 1996; 75:17-28.
3. Helbig G, Kyrcz-Krzemien S. Diagnostic and therapeutic management in patients with hypereosinophilic syndromes. Pol Arch Med Wewn 2011; 121:44-52.
4. Szczeklik W, Sokolowska BM, Zuk J, Mastalerz L, Szczeklik A, Musial J. The course of asthma in Churg-Strauss syndrome. J Asthma 2011; 48:183-7.
5. Serhan CN. Novel lipid mediators and resolution mechanisms in acute inflammation: to resolve or not? Am J Pathol 2010; 177:1576-91.
6. Dobrian AD, Lieb DC, Cole BK, Taylor-Fishwick DA, Chakrabarti SK, Nadler JL. Functional and pathological roles of the 12- and 15-lipoxygenases. Prog Lipid Res 2011; 50:115-31.
7. Levy BD, De Sanctis GT, Devchand PR et al. Lipoxins and aspirin-triggered lipoxins in airway responses. Adv Exp Med Biol 2003; 525:19-23.
8. Sachs-Olsen C, Sanak M, Lang AM et al. Eoxins: a new inflammatory pathway in childhood asthma. J Allergy Clin Immunol 2010; 126:859-67.
9. Nigam S. Hepoxilins: novel enzymatic pathways and clinical significance. FEBS J 2007; 274:3493.
10. Jakiela B, Szczeklik W, Sokolowska B et al. Intrinsic pathway of apoptosis in peripheral blood eosinophils of Churg-Strauss syndrome. Rheumatology (Oxford) 2009; 48:1202-7.
11. Simon HU, Rothenberg ME, Bochner BS et al. Refining the definition of hypereosinophilic syndrome. J Allergy Clin Immunol 2010; 126:45-9.
12. Bandeira-Melo C, Weller PF. Eosinophils and cysteinyl leukotrienes. Prostaglandins Leukot Essent Fatty Acids 2003; 69:135-43.
13. Roufosse F, Weller PF. Practical approach to the patient with hypereosinophilia. J Allergy Clin Immunol 2010; 126:39-44.
14. Humbles AA, Lloyd CM, McMillan SJ et al. A critical role for eosinophils in allergic airways remodeling. Science 2004; 305:1776-9.
15. Higashi N, Mita H, Taniguchi M et al. Urinary eicosanoid and tyrosine derivative concentrations in patients with vasculitides. J Allergy Clin Immunol 2004; 114:1353-8.
16. Nakamura M, Ueda N, Kishimoto K, Yoshimoto T, Yamamoto S, Ishimura K. Immunocytochemical localization of platelet-type arachidonate 12-lipoxygenase in mouse blood cells. J Histochem Cytochem 1995; 43:237-44.
17. Masi AT, Hunder GG, Lie JT et al. The american college of rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum 1990; 33:1094-100.
18. Suppiah R, Mukhtyar C, Flossmann O et al. A cross-sectional study of the birmingham vasculitis activity score version 3 in systemic vasculitis. Rheumatology (Oxford) 2011; 50:899-905.
19. National Asthma Education and Prevention Program (National Heart Lung and Blood Institute). Third expert panel on the management of asthma., guidelines for the diagnosis and management of asthma: summary report 2007. Bethesda, MD, USA: U.S. Dept. of Health and Human Services, National Institues of Health, National Heart, Lung, and Blood Institute, 2008.
20. Nizankowska-Mogilnicka E, Bochenek G, Mastalerz L et al. EAACI/GA2LEN guideline: aspirin provocation tests for diagnosis of aspirin hypersensitivity. Allergy 2007; 62:1111-8.
21. Chusid MJ, Dale DC, West BC, Wolff SM. The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Medicine (Baltimore) 1975; 54:1-27.
22. Horvath IdJ JC. Exhaled Biomarkers. In: Larsson K ed. European Respiratory monograph: European Respiratory Society. Lausanne: European Respiratory Society, 2010:250.
23. Sanak M, Gielicz A, Nagraba K, Kaszuba M, Kumik J, Szczeklik A. Targeted eicosanoids lipidomics of exhaled breath condensate in healthy subjects. J Chromatogr B Analyt Technol Biomed Life Sci 2010; 878:1796-800.
24. Sanak M, Gielicz A, Bochenek G, Kaszuba M, Nizankowska-Mogilnicka E, Szczeklik A. Targeted eicosanoid lipidomics of exhaled breath condensate provide a distinct pattern in the aspirin-intolerant asthma phenotype. J Allergy Clin Immunol 2011; 127:1141-7.
25. British Thoracic Society Bronchoscopy Guidelines Committee, a Subcommittee of Standards of Care Committee of British Thoracic Society. British Thoracic Society guidelines on diagnostic flexible bronchoscopy. Thorax 2001; 56(Suppl. 1):i1-21.
26. [No authors listed]. Bronchoalveolar lavage constituents in healthy individuals, idiopathic pulmonary fibrosis, and selected comparison groups. The BAL cooperative group steering committee. Am Rev Respir Dis 1990; 141:S169-202.
27. Moore WC, Bleecker ER, Curran-Everett D et al. Characterization of the severe asthma phenotype by the national heart, lung, and blood institute's severe asthma research program. J Allergy Clin Immunol 2007; 119:405-13.
28. Brusasco V, Crapo R, Viegi G. Coming together: the ATS/ERS consensus on clinical pulmonary function testing. Eur Respir J 2005; 26:1-2.
29. Kuhn H, O'Donnell VB. Inflammation and immune regulation by 12/15-lipoxygenases. Prog Lipid Res 2006; 45:334-56.
30. Andersson CK, Claesson HE, Rydell-Tormanen K, Swedmark S, Hallgren A, Erjefalt JS. Mice lacking 12/15-lipoxygenase have attenuated airway allergic inflammation and remodeling. Am J Respir Cell Mol Biol 2008; 39:648-56.
31. Vincent C, Fiancette R, Donnard M et al. 5-LOX, 12-LOX and 15-LOX in immature forms of human leukemic blasts. Leuk Res 2008; 32:1756-62.
32. Piao YS, Du YC, Oshima H et al. Platelet-type 12-lipoxygenase accelerates tumor promotion of mouse epidermal cells through enhancement of cloning efficiency. Carcinogenesis 2008; 29:440-7.
33. Honn KV, Tang DG, Gao X et al. 12-lipoxygenases and 12(S)-HETE: role in cancer metastasis. Cancer Metastasis Rev 1994; 13:365-96.
34. Wang MM, Reynaud D, Pace-Asciak CR. In vivo stimulation of 12(S)-lipoxygenase in the rat skin by bradykinin and platelet activating factor: formation of 12(S)-HETE and hepoxilins, and actions on vascular permeability. Biochim Biophys Acta 1999; 1436:354-62.
35. Ulfman LH, Joosten DP, van Aalst CW et al. Platelets promote eosinophil adhesion of patients with asthma to endothelium under flow conditions. Am J Respir Cell Mol Biol 2003; 28:512-9.
36. Arnoux B, Denjean A, Page CP, Nolibe D, Morley J, Benveniste J. Accumulation of platelets and eosinophils in baboon lung after paf-acether challenge. Inhibition by ketotifen. Am Rev Respir Dis 1988; 137:855-60.
37. Herd CM, Page CP. Pulmonary immune cells in health and disease: platelets. Eur Respir J 1994; 7:1145-60.
38. Coyle AJ, Page CP, Atkinson L, Flanagan R, Metzger WJ. The requirement for platelets in allergen-induced late asthmatic airway obstruction. Eosinophil infiltration and heightened airway responsiveness in allergic rabbits. Am Rev Respir Dis 1990; 142:587-93.
39. Tomasson G, Lavalley M, Tanriverdi K et al. Relationship between markers of platelet activation and inflammation with disease activity in Wegener's granulomatosis. J Rheumatol 2011; 38:1048-54.
40. Szczeklik W, Sokolowska B, Mastalerz L et al. Pulmonary findings in Churg-Strauss syndrome in chest X-rays and high resolution computed tomography at the time of initial diagnosis. Clin Rheumatol 2010; 29:1127-34.
41. Szczeklik W, Grzanka P, Mastalerz L, Sokolowska B, Musial J. Lung involvement in Churg-Strauss syndrome as related to the activity of the disease. Allergy 2010; 65:1484-5.
42. Profita M, Sala A, Riccobono L et al. 15-Lipoxygenase expression and 15(S)-hydroxyeicoisatetraenoic acid release and reincorporation in induced sputum of asthmatic subjects. J Allergy Clin Immunol 2000; 105:711-6.
43. Chu HW, Balzar S, Westcott JY et al. Expression and activation of 15-lipoxygenase pathway in severe asthma: relationship to eosinophilic phenotype and collagen deposition. Clin Exp Allergy 2002; 32:1558-65.
44. Salari H, Schellenberg RR. Stimulation of human airway epithelial cells by platelet activating factor (PAF) and arachidonic acid produces 15-hydroxyeicosatetraenoic acid (15-HETE) capable of contracting bronchial smooth muscle. Pulm Pharmacol 1991; 4:1-7.
45. Jackson AS, Sandrini A, Campbell C, Chow S, Thomas PS, Yates DH. Comparison of biomarkers in exhaled breath condensate and bronchoalveolar lavage. Am J Respir Crit Care Med 2007; 175:222-7.